Search results for "vaccination"

showing 10 items of 660 documents

Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.

2021

Abstract In the midst of the COVID-19 pandemic, different vaccines in front of SARS-CoV-2 have been approved and administered in different vulnerable populations. As patients with cancer were excluded from pivotal trials of vaccination, little is known on their immunogenic response to these vaccines, particularly in patients with severely impaired immune system. In response to that uncertainty, the Spanish Society of Hematology and Hemotherapy launched an initiative aimed to provide recommendations for vaccination of the main hematological conditions. This document is based on the available information on COVID-19 outcomes, prior knowledge on vaccination in hematological patients, recent pu…

Cancer Researchmedicine.medical_specialtyCOVID-19 VaccinesConsensusCoronavirus disease 2019 (COVID-19)myeloproliferative neoplasmSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)lymphomaReviewstem cell transplantationCOVID-19 SARS-CoV-2 vaccine acute leukemia allogeneic stem cell transplantation lymphoma myelodisplastic syndrome myeloproliferative neoplasm onco-hematology stem cell transplantation vaccination consensusallogeneic stem cell transplantationSARS-CoV-2 vaccineInternal medicinePandemicmedicineHemotherapyHumansIn patientacute leukemiaIntensive care medicineExpert TestimonyPandemicsonco-hematologyHematologySARS-CoV-2business.industryVaccinationCOVID-19Expert consensusHematologyVaccinationvaccination consensusOncologymyelodisplastic syndromebusiness
researchProduct

P-149: Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma

2021

We evaluated the safety and immunogenicity of the BNT162b2 vaccine in 52 patients with multiple myeloma (MM). Median age was 71.3 (range, 39.6-90.8) years. 26 (50%) patients had received active treatment including an immunomodulatory drug (IMiD) (n=21), an anti-CD38 monoclonal antibody (n=11) and/or a proteasome inhibitor (n=4). 21 had received previous treatment interrupted at a median of 27.5 (range, 3.5-169.3) months before first vaccine inoculum. 5 patients had indolent untreated MM. 35 patients had a history of autologous hematopoietic cell transplantation (HSCT) performed at a median of 44.4 (range, 3.5-169.3) months before first vaccine inoculum. The vaccination was well tolerated wi…

Cancer Researchmedicine.medical_specialtybiologybusiness.industryImmunogenicityELISPOTHematologymedicine.diseaseGastroenterologyPoster PresentationsVaccinationTransplantationOncologyInternal medicinemedicinebiology.proteinSeroconversionAntibodybusinessAdverse effectMultiple myelomaClinical Lymphoma Myeloma and Leukemia
researchProduct

mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA

2013

Abstract Vaccination with in vitro transcribed RNA encoding tumor antigens is an emerging approach in cancer immunotherapy. Attempting to further improve RNA vaccine efficacy, we have explored combining RNA with immunomodulators such as rapamycin. Rapamycin, the inhibitor of mTOR, was used originally for immunosuppression. Recent reports in mouse systems, however, suggest that mTOR inhibition may enhance the formation and differentiation of the memory CD8+ T-cell pool. Because memory T-cell formation is critical to the outcome of vaccination aproaches, we studied the impact of rapamycin on the in vivo primed RNA vaccine-induced immune response using the chicken ovalbumin-expressing B16 mela…

Cancer Researchmedicine.medical_treatmentImmunologyMelanoma ExperimentalCD8-Positive T-LymphocytesBiologyCancer VaccinesLymphocytes Tumor-InfiltratingImmune systemAntigenCancer immunotherapyAntigens NeoplasmIn vivomedicineAnimalsRNA NeoplasmPI3K/AKT/mTOR pathwaySirolimusVaccines SyntheticAntibiotics AntineoplasticTOR Serine-Threonine KinasesVaccinationRNACell DifferentiationCombined Modality TherapyMice Inbred C57BLVaccinationImmunologyCancer researchFemaleDrug Screening Assays AntitumorImmunologic MemoryCD8Cancer Immunology Research
researchProduct

Heat Shock Protein Vaccines Against Cancer

1993

Vaccination of mice with heat shock proteins (HSPs) derived from a tumor makes the mice resistant to the tumor from which the HSP was obtained. This phenomenon has been demonstrated with three HSPs--gp96, hsp90, and hsp70. Vaccination with HSPs also elicits antigen-specific cytotoxic T lymphocytes (CTLs). The specific immunogenicity of HSPs derives apparently, not from the HSPs per se, but from the peptides bound to them. These observations provide the basis for a new generation of vaccines against cancer. The HSP-based cancer vaccines circumvent two of the most intractable hurdles to cancer immunotherapy. One of them is the possibility that human cancers, like cancers of experimental anima…

Cancer Researchmedicine.medical_treatmentImmunologychemical and pharmacologic phenomenaBiologyInfectionsEpitopeMiceImmune systemAntigenCancer immunotherapyHeat shock proteinmedicineAnimalsImmunology and AllergyCytotoxic T cellHeat-Shock ProteinsPharmacologyMice Inbred BALB CMice Inbred C3HHistocompatibility Antigens Class IVaccinationCancerhemic and immune systemsImmunotherapymedicine.diseaseImmunologySarcoma ExperimentalT-Lymphocytes CytotoxicJournal of Immunotherapy
researchProduct

Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines.

2013

Genetically modified cells have been shown to be one of the most effective cancer vaccine strategies. An evaluation is made of the efficacy of both preventive and therapeutic antitumor vaccines against murine melanoma, using C57BL/6 mice and irradiated B16 tumor cells expressing granulocyte and macrophage colony-stimulating factor (GM-CSF), interleukin-12 (IL-12) or both. Tumor was transplanted by the injection of wild-type B16 cells. Tumor growth and survival were measured to evaluate the efficacy of vaccination. Specific humoral response and immunoglobulin G (IgG) switch were evaluated measuring total IgG and IgG1 and IgG2a subtypes against tumor membrane proteins of B16 cells. In prevent…

Cancer Researchmedicine.medical_treatmentMelanoma ExperimentalBiologyTransfectionCancer VaccinesImmunotherapy AdoptiveImmunoglobulin GMicemedicineMacrophageAnimalsMolecular BiologyMicroscopy ConfocalMelanomaGranulocyte-Macrophage Colony-Stimulating FactorImmunotherapymedicine.diseaseInterleukin-12Survival AnalysisGenetically modified organismVaccinationMice Inbred C57BLImmunologyInterleukin 12biology.proteinMolecular MedicineCancer vaccineCancer gene therapy
researchProduct

Robust Antigen-Specific T Cell Activation within Injectable 3D Synthetic Nanovaccine Depots

2021

Contains fulltext : 244693.pdf (Publisher’s version ) (Open Access) Synthetic cancer vaccines may boost anticancer immune responses by co-delivering tumor antigens and adjuvants to dendritic cells (DCs). The accessibility of cancer vaccines to DCs and thereby the delivery efficiency of antigenic material greatly depends on the vaccine platform that is used. Three-dimensional scaffolds have been developed to deliver antigens and adjuvants locally in an immunostimulatory environment to DCs to enable sustained availability. However, current systems have little control over the release profiles of the cargo that is incorporated and are often characterized by an initial high-burst release. Here,…

Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]T-LymphocytesT cellBiomedical Engineering02 engineering and technologySDG 3 – Goede gezondheid en welzijnantigen-specific T cellsCancer VaccinesArticleBiomaterials03 medical and health sciencesbiomaterial-based scaffoldsImmune systemAntigenSDG 3 - Good Health and Well-beingAntigen specificControlled deliverymedicineLactic Aciddendritic cells030304 developmental biology0303 health sciencesChemistryBiomaterial021001 nanoscience & nanotechnologyCell biologymedicine.anatomical_structureDelivery efficiencynanoparticles0210 nano-technologycancer vaccinationNanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]Polyglycolic Acid
researchProduct

Self-adjuvanting C18 lipid vinil sulfone-PP2A vaccine: study of the induced immunomodulation against

2017

Despite the importance of the adjuvant in the immunization process, very few adjuvants merge with the antigens in vaccines. A synthetic self-adjuvant oleic-vinyl sulfone (OVS) linked to the catalytic region of recombinant serine/threonine phosphatase 2A from the nematode Angiostrongylus costaricensis (rPP2A) was used for intranasal immunization in mice previously infected with Trichuris muris. The animal intranasal immunization with rPP2A-OVS showed a reduction of 99.01% in the number of the nematode eggs and 97.90% in adult. The immunohistochemical analysis of the intestinal sections showed that in immunized animals with lipopeptide the mucus was significantly higher than in the other expe…

Chemokine CCL111001Gene Expressionchemical and pharmacologic phenomenachemokines199LipopeptidesMiceMice Inbred AKRAdjuvants ImmunologicAnimalsAmino Acid SequenceProtein Phosphatase 2SulfonesTrichuriasisIntestinal Mucosalipid vinyl sulfoneParasite Egg CountAdministration IntranasalChemokine CCL20Vaccines Conjugate31InterleukinsResearchHelminth Proteins200Recombinant ProteinsTrichuris muris vaccinationcytokinesTrichurisTh17 CellsFemaleSequence AlignmentResearch Articleself-assembling lipopeptide rPP2AOpen biology
researchProduct

Cost analysis of a vaccination strategy for respiratory syncytial virus (RSV) in a network model

2010

[EN] In this paper an age-structured mathematical model for respiratory syncytial virus (RSV) is proposed where children younger than one year old, who are the most affected by this illness, are specially considered. Real data of hospitalized children in the Spanish region of Valencia are used in order to determine some seasonal parameters of the model. Once the parameters are determined, we propose a complete stochastic network model to study the seasonal evolution of the respiratory syncytial virus (RSV) epidemics. In this model every susceptible individual can acquire the disease after a random encounter with any infected individual in the social network. The edges of a complete graph co…

Cost estimationbusiness.industryStochastic modellingDiseaseBiologyRespiratory syncytial virusmedicine.disease_causeVaccination strategyComputer Science ApplicationsVaccinationRespiratory syncytial virus (RSV)Network mathematical modelSusceptible individualModeling and SimulationModelling and SimulationStatisticsmedicineCost analysisProbability distributionArtificial intelligencebusinessMATEMATICA APLICADANetwork modelMathematical and Computer Modelling
researchProduct

Causes of and prevention strategies for hepatocellular carcinoma.

2012

Hepatocellular carcinoma (HCC) is a challenging malignancy of global importance. It is associated with a high rate of mortality and its prevalence in the United States and in Western Europe is increasing. Cirrhosis is the strongest and the most common known risk factor for HCC, usually due to hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. However, different lines of evidence identify in non-alcoholic fatty liver disease (NAFLD) a possible relevant risk factor for occurrence of HCC. Given the continuing increase in the prevalence of obesity and diabetes, the incidence of non-alcoholic steatohepatitis-related HCC may also be expected to increase, and a potential role of behav…

Counselingmedicine.medical_specialtyCirrhosisCarcinoma HepatocellularHepatitis C virusDiseasemedicine.disease_causeGastroenterologyChemopreventionInternal medicineMedicineHumansRisk factorHepatitis B virusbusiness.industryIncidence (epidemiology)Hepatocellular carcinoma primary prevention chemopreventionFatty liverLiver NeoplasmsVaccinationHematologymedicine.diseaseHepatitis BHepatitis Cdigestive system diseasesOncologyHepatocellular carcinomaControlled Clinical Trials as TopicInterferonsbusinessSeminars in oncology
researchProduct

Determinants of vaccine hesitancy and effectiveness of vaccination counseling interventions among a sample of the general population in Palermo, Ital…

2020

Counteract vaccine hesitancy is a public health priority. Main objectives of the cross-sectional study conducted were to evaluate knowledge, attitudes, and behaviors regarding vaccination issues, to estimate the prevalence of vaccine hesitancy and to estimate the effectiveness of vaccination counseling on community advocacy in a sample of general population. An anonymous validated questionnaire was administered in April 2017 at the main shopping center of Palermo and was followed by tailored vaccination counseling interventions. To estimate the effectiveness of the interventions four main connection parameters to the vaccinarsi.org website were evaluated, in the two months before and after …

Counselingmedicine.medical_specialtyHealth Knowledge Attitudes Practicevaccination confidence030231 tropical medicineImmunologyPopulationPsychological interventionSample (statistics)general population03 medical and health sciences0302 clinical medicineVaccination RefusalEnvironmental healthmedicineImmunology and AllergyHumansvaccination counseling030212 general & internal medicineinternet traffic indicatorseducationhealth advocacyVaccine hesitancyPharmacologyeducation.field_of_studyVaccinesbusiness.industryPublic healthVaccinationPatient Acceptance of Health Careweb searchVaccinationHealth advocacyCross-Sectional StudiesItalyinternet traffic indicatorbusinessResearch ArticleResearch PaperHuman vaccinesimmunotherapeutics
researchProduct